4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics (Nasdaq: FDMT) announced that on October 14, 2025 its compensation committee granted 25,450 Restricted Stock Units (RSUs) to three new non-executive employees under the company’s 2025 Employment Inducement Award Plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
4D Molecular Therapeutics (Nasdaq: FDMT) announced that on October 14, 2025 its compensation committee granted 25,450 Restricted Stock Units (RSUs) to three new non-executive employees under the company’s 2025 Employment Inducement Award Plan.
The inducement plan was approved by the board in February 2025 and is being used under Nasdaq Rule 5635(c)(4) to grant equity awards to attract new hires. The announcement identifies the grant date and plan authority but does not disclose recipient names, vesting terms, or share-count impact.
Details
News Market Reaction – FDMT
On Oct 20, the first trading day after this news, FDMT closed 14.53% above the previous close.
Data tracked by StockTitan Argus for the Oct 20 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on October 14, 2025, the compensation committee of the Company’s board of directors granted three new non-executive employees 25,450 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Jenn Gordon
dna Communications
Media@4DMT.com
Investors:
Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.